This may add evidence to the established observation of a close link between the dominant clinical symptoms and the peak regions of the most elevated tau pathology in both typical and atypical AD (Dronse et al., 2016; Ossenkoppele et al., 2016; Bejanin et al., 2017; Bischof et al., 2017). The gene discussed is MAPT; the disease is Alzheimer disease.